Binkow & Goldberg LLP, representing investors of Geron
Corporation ("Geron" or the "Company") (NASDAQ:GERN), has filed a
class action lawsuit in the United States District Court for the
Northern District of California on behalf of a class (the "Class")
comprising all purchasers of Geron securities between June 16,
2013 and March 11, 2014, inclusive (the "Class Period").
Please contact Glancy Binkow & Goldberg LLP, toll-free at (888) 773-9224
or at (212) 682-5340, or by email to firstname.lastname@example.org
to discuss this matter.
Geron is a clinical stage biopharmaceutical company developing
first-in-class therapies for cancer. The Company's sole product
candidate, imetelstat, is designed to inhibit cancer cell replication in
hematologic myeloid malignancies such as myelofibrosis or acute
myelogenous leukemia. The Complaint alleges that throughout the Class
Period defendants misrepresented or failed to disclose that: (1)
persistent low-grade liver function test (LFT) abnormalities had been
observed in the Phas 2 study of imetelstat in essential thrombocythemia
(ET) or polycythemia vera (PV) patients; (2) there was a potential risk
of chronic liver injury following long-term exposure to imetelstat; and
(3), as a result of the foregoing, defendants' positive statements about
the Company and the prospects for imetelstat lacked any reasonable basis
and/or were materially false and misleading at all relevant times.
On March 12, 2014, Geron disclosed that it had received verbal notice
from the U.S. Food and Drug Administration that Geron's Investigational
New Drug application for imetelstat has been placed on full clinical
hold - an order to a trial sponsor to suspend an ongoing clinical trial
or delay a proposed trial - affecting all ongoing company-sponsored
clinical trials, and that the FDA expressed concern about whether the
LFT abnormalities were reversible. As a result, Geron informed investors
that the clinical hold would affect the remaining eight patients in the
Company's Phase 2 study in ET/PV and the remaining two patients in the
company's Phase 2 study in multiple myeloma. Also, the Company indicated
that a planned Phase 2 clinical trial in myelofibrosis would likely be
delayed due to the clinical hold.
If you are a member of the Class described above, you may move the Court
no later than 60 days from the date of this Notice, to serve as lead
plaintiff, if you meet certain legal requirements. To be a member of the
Class you need not take any action at this time; you may retain counsel
of your choice or take no action and remain an absent member of the
Class. If you wish to learn more about this action, or have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to email@example.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To NFVZone's Homepage ]